MSFT 435.0 0.7061% AAPL 230.65 -1.2924% NVDA 139.965 -0.9097% GOOGL 176.965 4.2934% GOOG 178.65 4.3882% AMZN 193.73 1.5197% META 594.31 0.1736% AVGO 177.28 -1.0935% TSLA 262.2401 1.0481% TSM 195.14 -0.914% LLY 831.501 -7.977% V 291.3 3.3418% JPM 224.685 0.8008% UNH 564.77 0.4696% NVO 113.15 1.0448% WMT 81.58 -0.1469% LVMUY 134.2 -1.4033% XOM 117.0342 -0.2096% LVMHF 670.0 -1.3008% MA 513.51 1.4281%

Eagle Pharmaceuticals Inc

Healthcare US EGRX

0.6USD
0.20(50.00%)

Last update at 2024-10-30T18:23:00Z

Day Range

0.450.65
LowHigh

52 Week Range

3.5023.52
LowHigh

Fundamentals

  • Previous Close 0.40
  • Market Cap48.46M
  • Volume54845
  • P/E Ratio4.40
  • Dividend Yield-%
  • EBITDA62.33M
  • Revenue TTM257.55M
  • Revenue Per Share TTM19.68
  • Gross Profit TTM 221.67M
  • Diluted EPS TTM0.85

Analyst Recommendations

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax 61.43M -4.54800M 22.68M 22.00M 34.04M
Minority interest - - - - -
Net income 35.64M -8.62700M 11.99M 14.31M 31.90M
Selling general administrative 106.63M 75.32M 78.60M 76.37M 60.51M
Selling and marketing expenses - - - - -
Gross profit 221.67M 129.37M 142.34M 135.00M 151.40M
Reconciled depreciation 12.02M 3.76M 4.77M 4.65M 3.67M
Ebit 53.45M -2.91300M 25.25M 21.82M 46.63M
Ebitda 65.48M 0.85M 30.02M 29.34M 50.30M
Depreciation and amortization 12.02M 3.76M 4.77M 7.52M 3.67M
Non operating income net other -15.48200M -5.68200M -7.70000M 2.87M 0.16M
Operating income 53.45M -2.91300M 25.25M 21.82M 36.62M
Other operating expenses 235.65M 168.78M 154.85M 174.08M 166.84M
Interest expense 4.04M 1.64M 2.58M 2.69M 2.74M
Tax provision 25.79M 4.08M 10.69M 7.68M 2.13M
Interest income 0.27M 0.56M 0.56M 2.17M 0.16M
Net interest income -3.77400M -1.07500M -2.01500M -0.51700M -2.57800M
Extraordinary items - - - - -
Non recurring 9.48M 10.65M 11.82M 13.01M 30.16M
Other items - - - - -
Income tax expense 25.79M 4.08M 10.69M 7.68M 2.13M
Total revenue 316.61M 171.55M 187.80M 195.89M 213.31M
Total operating expenses 140.71M 126.60M 109.38M 113.18M 104.93M
Cost of revenue 94.94M 42.18M 45.47M 60.90M 61.92M
Total other income expense net 7.98M -1.63500M -2.57700M 0.18M -9.85200M
Discontinued operations - - - - -
Net income from continuing ops 35.64M -8.62700M 11.99M 14.31M 31.90M
Net income applicable to common shares 35.64M -8.62700M 11.99M 14.31M 31.90M
Preferred stock and other adjustments - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 406.16M 253.73M 253.19M 254.55M 238.60M
Intangible assets 118.33M 10.67M 12.92M 15.58M 18.10M
Earning assets - - - - -
Other current assets 13.20M 11.89M 1.60M 15.10M 10.26M
Total liab 172.60M 77.28M 67.18M 75.38M 77.84M
Total stockholder equity 233.56M 176.45M 186.01M 179.17M 160.76M
Deferred long term liab - - - - -
Other current liab 85.84M 6.97M 3.08M 2.30M 1.81M
Common stock 0.02M 0.02M 0.02M 0.02M 0.02M
Capital stock 0.02M 0.02M 0.02M 0.02M 0.02M
Retained earnings 111.50M 75.86M 84.49M 72.50M 58.19M
Other liab 3.79M 2.90M 3.96M 3.00M -
Good will 45.03M 39.74M 39.74M 39.74M 39.74M
Other assets 52.88M 29.08M 32.39M 13.86M 14.52M
Cash 55.32M 97.66M 103.16M 109.78M 78.79M
Cash and equivalents - - - - -
Total current liabilities 111.09M 74.38M 38.09M 38.82M 39.69M
Current deferred revenue - 25.36M 20.74M 26.06M 21.71M
Net debt 7.14M -72.05200M -66.06100M -71.21800M -34.38600M
Short term debt 6.25M 25.61M 8.00M 5.00M 6.25M
Short long term debt 6.25M 25.61M 8.00M 5.00M 6.25M
Short long term debt total 62.47M 25.61M 37.09M 38.56M 44.41M
Other stockholder equity 123.15M 100.67M 101.50M 106.66M 102.56M
Property plant equipment 1.17M 1.64M 2.08M 2.20M 2.40M
Total current assets 188.75M 172.61M 166.06M 179.45M 163.84M
Long term investments - - - - -
Net tangible assets 70.20M 126.04M 133.35M 123.85M 102.92M
Short term investments - - - - -
Net receivables 72.44M 41.15M 51.12M 48.00M 66.49M
Long term debt 56.22M - 25.14M 33.56M 38.16M
Inventory 47.79M 21.91M 8.07M 6.57M 8.30M
Accounts payable 18.99M 16.43M 6.27M 5.46M 9.92M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -1.11200M -0.09400M - -4.31900M -3.34700M
Additional paid in capital - - - - -
Common stock total equity 0.02M 0.02M 0.02M 0.02M 0.02M
Preferred stock total equity - - - - -
Retained earnings total equity 111.50M 75.86M 84.49M 72.50M 58.19M
Treasury stock -243.11500M -225.11100M -203.89800M -171.86100M -153.90000M
Accumulated amortization - - - - -
Non currrent assets other 25.73M 10.28M 17.21M 3.91M 0.69M
Deferred long term asset charges - - - - -
Non current assets total 217.41M 81.13M 87.12M 75.11M 74.76M
Capital lease obligations 5.32M 4.21M 3.96M 3.00M -
Long term debt total 56.22M - 25.14M 33.56M 38.16M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -86.83000M -5.32300M -18.24700M -0.77700M -0.13300M
Change to liabilities 46.55M 17.93M -3.62300M -0.38800M 6.06M
Total cashflows from investing activities -86.83000M -5.32300M -18.24700M -0.77700M -0.13300M
Net borrowings 11.40M -8.00000M -5.00000M -6.32600M -3.75000M
Total cash from financing activities -6.20900M -28.39200M -37.87000M -24.22500M -88.11700M
Change to operating activities 19.80M 3.68M 4.63M -1.37300M 12.40M
Net income 35.64M -8.62700M 11.99M 14.31M 31.90M
Change in cash -42.33800M -5.49600M -6.62000M 30.98M -35.86600M
Begin period cash flow 97.66M 103.16M 109.78M 78.79M 114.66M
End period cash flow 55.32M 97.66M 103.16M 109.78M 78.79M
Total cash from operating activities 50.70M 28.22M 49.50M 55.99M 52.38M
Issuance of capital stock - - - - -
Depreciation 12.02M 3.76M 4.77M 4.65M 3.67M
Other cashflows from investing activities -86.65200M -5.00000M -17.50000M -17.50000M -17.50000M
Dividends paid - - - - -
Change to inventory -8.33900M -13.83300M -1.50900M 1.74M -5.55600M
Change to account receivables -30.83200M 9.53M -3.11300M 18.48M -12.66500M
Sale purchase of stock -18.00400M -21.21300M -34.99900M -17.96100M -73.10500M
Other cashflows from financing activities 79.03M 0.82M 112.13M -0.26400M -11.26200M
Change to netincome 17.73M 21.42M 28.55M 22.15M 24.32M
Capital expenditures 0.18M 0.32M 0.75M 0.78M 0.13M
Change receivables -30.83200M 9.53M -3.11300M 18.48M -12.66500M
Cash flows other operating -22.53600M -2.43500M 13.25M -5.44000M 4.27M
Exchange rate changes - - - - -
Cash and cash equivalents changes -42.33800M -5.49600M -6.62000M 30.98M -35.86600M
Change in working capital -16.40400M 9.54M 0.82M 14.39M -7.88900M
Stock based compensation 16.45M 19.55M 24.76M 22.00M 19.08M
Other non cash items 11.31M 7.61M 8.68M 0.48M 8.09M
Free cash flow 50.52M 27.90M 48.75M 55.21M 52.25M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
EGRX
Eagle Pharmaceuticals Inc
0.20 50.00% 0.60 4.40 11.34 0.23 0.24 0.45 2.07
ZTS
Zoetis Inc
0.81 0.45% 182.08 40.18 30.96 10.67 17.60 11.27 26.18
MKKGY
Merck KGaA ADR
-0.1 0.30% 32.87 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien
- -% 162.43 21.73 14.95 3.16 2.15 3.56 12.82
TAK
Takeda Pharmaceutical Co Ltd ADR
0.04 0.29% 13.89 32.67 11.53 0.01 0.87 0.02 0.07

Reports Covered

Stock Research & News

Profile

Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.

Eagle Pharmaceuticals Inc

50 Tice Boulevard, Woodcliff Lake, NJ, United States, 07677

Key Executives

Name Title Year Born
Mr. Scott L. Tarriff Founder, Pres, CEO & Director 1960
Mr. Brian Joseph Cahill Chief Financial Officer 1969
Mr. Ryan Debski Exec. VP, Gen. Counsel & Chief Compliance Officer NA
Mr. Daniel O'Connor Exec. VP, Chief Strategy Officer & Head of Corp. Devel. 1980
Mr. John Kimmet Exec. VP of Marketing Oncology & Acute Care NA
Dr. Valentin R. Curt M.D. Sr. VP of Clinical Drug Devel. NA
Dr. Gaozhong Zhu Ph.D. Sr. VP of Pharmaceutical Devel. NA
Ms. Debra M. Hussain Sr. VP & Head of Commercial NA
Mr. Reiner Nowak Exec. NA
Mr. Michael Graves Interim Principal Executive Officer & Executive Chairman of the Board 1963

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.